268 related articles for article (PubMed ID: 23509459)
1. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
Giunti S; Antonelli A; Amorosi A; Santarpia L
Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
Almeida MQ; Hoff AO
Curr Opin Oncol; 2012 May; 24(3):229-34. PubMed ID: 22343387
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
4. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
5. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
6. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
7. Treating medullary thyroid cancer in the age of targeted therapy.
Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
[TBL] [Abstract][Full Text] [Related]
8. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
9. Advances and controversies in the management of medullary thyroid carcinoma.
Maia AL; Wajner SM; Vargas CV
Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
[TBL] [Abstract][Full Text] [Related]
10. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
11. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
[TBL] [Abstract][Full Text] [Related]
12. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract][Full Text] [Related]
13. Update on the cytologic and molecular features of medullary thyroid carcinoma.
Pusztaszeri MP; Bongiovanni M; Faquin WC
Adv Anat Pathol; 2014 Jan; 21(1):26-35. PubMed ID: 24316908
[TBL] [Abstract][Full Text] [Related]
14. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib for the treatment of metastatic medullary thyroid cancer.
Degrauwe N; Sosa JA; Roman S; Deshpande HA
Clin Med Insights Oncol; 2012; 6():243-52. PubMed ID: 22723734
[TBL] [Abstract][Full Text] [Related]
16. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
17. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
18. Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors-A Retrospective Multi-Center Registry Analysis.
Koehler VF; Adam P; Fuss CT; Jiang L; Berg E; Frank-Raue K; Raue F; Hoster E; Knösel T; Schildhaus HU; Negele T; Siebolts U; Lorenz K; Allelein S; Schott M; Spitzweg C; Kroiss M;
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884466
[TBL] [Abstract][Full Text] [Related]
19. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]